A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.

ABSTRACT: Primary objectives: Overall survival between the two groups

DISEASE(S): Patient With Metastatic Colorectal Cancer,Colorectal Cancer Duke's D

PROVIDER: 2535860 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR